$BLAC
Bellevue Life Sciences Acquisition Corp.

2024 Q2 Form 10-K Financial Statement

#000119312524099137 Filed on April 17, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2023 Q4 2023
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $475.5K $861.9K $1.831M
YoY Change 69.67% 8518.9% 5073.22%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $475.5K $861.9K $1.831M
YoY Change 69.67% 8518.9% 5073.22%
Operating Profit
YoY Change
Interest Expense $465.5K $928.8K $2.775M
YoY Change -42.53%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$10.04K $66.87K $944.6K
YoY Change -101.89% -768.7% -2461.48%
Income Tax $87.26K $153.0K $540.8K
% Of Pretax Income 228.86% 57.25%
Net Earnings -$97.30K -$86.17K $403.8K
YoY Change -132.27% 761.7% -1241.01%
Net Earnings / Revenue
Basic Earnings Per Share -$0.02 $0.05
Diluted Earnings Per Share -$0.02 -$0.01 $0.05
COMMON SHARES
Basic Shares Outstanding 5.623M 9.055M shares 7.688M
Diluted Shares Outstanding 4.945M 7.720M

Balance Sheet

Concept 2024 Q2 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $119.1K $15.42K $15.42K
YoY Change -87.15% -87.15%
Cash & Equivalents $119.1K $15.42K
Short-Term Investments
Other Short-Term Assets $47.71K $7.210K $7.210K
YoY Change -20.48%
Inventory
Prepaid Expenses $47.71K $7.208K
Receivables
Other Receivables
Total Short-Term Assets $166.8K $22.63K $22.63K
YoY Change 182.87% -81.83% -81.14%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $20.47M $36.61M $36.61M
YoY Change -71.35%
Other Assets $0.00 $0.00
YoY Change -100.0% -100.0%
Total Long-Term Assets $20.47M $36.61M $36.61M
YoY Change -71.35% 3223.65% 3197.76%
TOTAL ASSETS
Total Short-Term Assets $166.8K $22.63K $22.63K
Total Long-Term Assets $20.47M $36.61M $36.61M
Total Assets $20.63M $36.63M $36.63M
YoY Change -71.14% 2887.94% 2877.86%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.052M $1.082M $1.082M
YoY Change 289.77% 3505.83% 3505.83%
Accrued Expenses $530.4K $360.0K $360.0K
YoY Change 3499.6% 3499.6%
Deferred Revenue
YoY Change
Short-Term Debt $1.498M $0.00 $0.00
YoY Change -100.0% -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.418M $2.038M $2.038M
YoY Change 531.38% 61.34% 61.77%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $3.418M $2.038M $2.038M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $5.488M $4.108M $4.108M
YoY Change 110.16% 225.19% 226.05%
SHAREHOLDERS EQUITY
Retained Earnings -$4.904M -$3.907M
YoY Change 134.1% 6150.41%
Common Stock $216.00 $216.00
YoY Change 0.0% 24.86%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$4.904M -$3.907M $32.52M
YoY Change
Total Liabilities & Shareholders Equity $20.63M $36.63M $36.63M
YoY Change -71.14% 2887.94% 2877.86%

Cashflow Statement

Concept 2024 Q2 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$97.30K -$86.17K $403.8K
YoY Change -132.27% 761.7% -1241.01%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$1.416M -$279.5K -$818.8K
YoY Change 304.68% 19233.32%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $17.20M $36.38M -$33.83M
YoY Change
Cash From Investing Activities $17.20M $36.38M -$33.83M
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $36.00M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -15.67M -36.14M 34.54M
YoY Change -72381.46% 27759.15%
NET CHANGE
Cash From Operating Activities -1.416M -279.5K -818.8K
Cash From Investing Activities 17.20M 36.38M -33.83M
Cash From Financing Activities -15.67M -36.14M 34.54M
Net Change In Cash 115.5K -42.55K -109.1K
YoY Change -132.99% -185.1% -191.1%
FREE CASH FLOW
Cash From Operating Activities -$1.416M -$279.5K -$818.8K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001840425
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
WA
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity Registrant Name
EntityRegistrantName
BELLEVUE LIFE SCIENCES ACQUISITION CORP.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity File Number
EntityFileNumber
001-41390
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-5052822
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
10900 NE 4th Street
CY2023 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 2300
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Bellevue
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
98004
CY2023 dei City Area Code
CityAreaCode
425
CY2023 dei Local Phone Number
LocalPhoneNumber
635-7700
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
true
CY2023Q2 dei Entity Public Float
EntityPublicFloat
70794000000000
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
5622954
CY2024Q2 us-gaap Debt Instrument Maturity Date Range End1
DebtInstrumentMaturityDateRangeEnd1
2024-05-14
CY2023 dei Auditor Name
AuditorName
WithumSmith+Brown, PC
CY2023 dei Auditor Location
AuditorLocation
New York, New York
CY2023 dei Auditor Firm
AuditorFirmId
100
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15419
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
124501
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
7208
CY2023Q4 us-gaap Assets Current
AssetsCurrent
22627
CY2022Q4 us-gaap Assets Current
AssetsCurrent
124501
CY2022Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
1101353
CY2023Q4 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
36605106
CY2023Q4 us-gaap Assets
Assets
36627733
CY2022Q4 us-gaap Assets
Assets
1225854
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1081753
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
34000
CY2023Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
524562
CY2023Q4 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
359957
CY2022Q4 blacu Accrued Offering Costs Current
AccruedOfferingCostsCurrent
12362
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
0
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
1200000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
72000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
17000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2038272
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1263362
CY2023Q4 blacu Deferred Underwriting Commissions
DeferredUnderwritingCommissions
2070000
CY2023Q4 us-gaap Liabilities
Liabilities
4108272
CY2022Q4 us-gaap Liabilities
Liabilities
1263362
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2155000
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2155000
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1725000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1725000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
216
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
173
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
24827
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-3907008
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-62508
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-3906792
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-37508
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
36627733
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1225854
CY2023 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1830700
CY2022 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
35388
CY2023 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-1830700
CY2022 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-35388
CY2023 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
2775291
CY2023 us-gaap Other Income
OtherIncome
2775291
CY2023 us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
944591
CY2022 us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
-35388
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
540811
CY2023 us-gaap Net Income Loss
NetIncomeLoss
403780
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-35388
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7688260
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1500000
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7719699
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1500000
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.05
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.05
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-2120
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-35388
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-37508
CY2023 us-gaap Stock And Warrants Issued During Period Value Preferred Stock And Warrants
StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
1236527
CY2023 blacu Accretion For Common Stock To Redemption Value
AccretionForCommonStockToRedemptionValue
-9449634
CY2023 us-gaap Net Income Loss
NetIncomeLoss
403780
CY2023 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
359957
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-3906792
CY2023 us-gaap Profit Loss
ProfitLoss
403780
CY2022 us-gaap Profit Loss
ProfitLoss
-35388
CY2023 us-gaap Interest Income Interest Earning Asset Increase Decrease
InterestIncomeInterestEarningAssetIncreaseDecrease
2775291
CY2023 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
7208
CY2023 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1035391
CY2022 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
31153
CY2023 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
524562
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-818766
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4235
CY2023 blacu Proceeds From Trust Account For Payment To Redeeming Stockholders
ProceedsFromTrustAccountForPaymentToRedeemingStockholders
35995728
CY2023 us-gaap Payments To Acquire Restricted Investments
PaymentsToAcquireRestrictedInvestments
180000
CY2023 blacu Cash Deposited In The Trust Account
CashDepositedInTheTrustAccount
70207500
CY2023 blacu Gain Loss From Trust Account To Pay Expenses
GainLossFromTrustAccountToPayExpenses
561957
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-33829815
CY2023 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
35995728
CY2023 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
59670000
CY2023 us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
1447273
CY2022 us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
683021
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
34539499
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
123979
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-109082
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
119744
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
124501
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4757
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15419
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
124501
CY2023 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
16249
CY2023Q4 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
359957
CY2023 us-gaap Payments For Underwriting Expense
PaymentsForUnderwritingExpense
2070000
CY2022 blacu Deferred Offering Costs Included In Accrued Offering Costs
DeferredOfferingCostsIncludedInAccruedOfferingCosts
12362
CY2023Q4 blacu Condition For Future Business Combination Number Of Businesses Minimum
ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum
1
CY2023 blacu Percentage Of Trust Account Required For Business Combination
PercentageOfTrustAccountRequiredForBusinessCombination
0.80
CY2023 blacu Threshold Percentage Of Outstanding Voting Securities Of Target To Be Acquired By Post Transaction Company To Complete Business Combination
ThresholdPercentageOfOutstandingVotingSecuritiesOfTargetToBeAcquiredByPostTransactionCompanyToCompleteBusinessCombination
0.50
CY2023Q4 us-gaap Assets Held In Trust
AssetsHeldInTrust
70207500
CY2023 us-gaap Debt Instrument Redemption Description
DebtInstrumentRedemptionDescription
The Company will provide its holders of the outstanding shares of its Common Stock sold in the Initial Public Offering (the “Public Stockholders”) with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a stockholder meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The Public Stockholders will be entitled to redeem their Public Shares (as described in Note 1) for a pro rata portion of the amount then in the Trust Account (initially anticipated to be $10.175 per Public Share plus any pro rata interest then in the Trust Account, net of taxes payable). The per share amount to be distributed to Public Stockholders who redeem their Public Shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters (as discussed in Note 5).
CY2023Q4 blacu Net Tangible Assets
NetTangibleAssets
5000001
CY2023 blacu Redemption Limit Percentage
RedemptionLimitPercentage
0.15
CY2023 blacu Percentage Obligation To Redeem Public Shares If Entity Does Not Complete Business Combination
PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination
1
CY2023 blacu Period To Consummate Business Combination
PeriodToConsummateBusinessCombination
P9M
CY2023 blacu Percentage Obligation To Redeem Public Shares If Entity Does Not Complete Business Combination
PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination
1
CY2023 blacu Maximum Allowed Dissolution Expenses
MaximumAllowedDissolutionExpenses
100000
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3432046
CY2024Q1 us-gaap Temporary Equity Redemption Price Per Share
TemporaryEquityRedemptionPricePerShare
10.49
CY2024Q1 us-gaap Temporary Equity Value Excluding Additional Paid In Capital
TemporaryEquityValueExcludingAdditionalPaidInCapital
35995728
CY2024Q1 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
36372335
CY2024Q1 blacu Interest Income Held In The Trust Account
InterestIncomeHeldInTheTrustAccount
561957
CY2023Q4 blacu Investment Of Cash In Trust Account
InvestmentOfCashInTrustAccount
180000
CY2023Q4 blacu Interest Income Held In The Trust Account
InterestIncomeHeldInTheTrustAccount
561957
CY2023Q4 us-gaap Cash
Cash
15419
CY2023Q4 us-gaap Debt Current
DebtCurrent
2015645
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Use of Estimates </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The preparation of financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the financial statements and the reported amounts of expenses during the reporting periods. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effects of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates. </div>
CY2023Q4 us-gaap Cash
Cash
15419
CY2022Q4 us-gaap Cash
Cash
124501
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2023Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Concentration of Credit Risk </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Deposit Insurance Corporation coverage of $250,000. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company’s financial condition, results of operations, and cash flows. </div>
CY2023 blacu Number Of Shares Issued Per Unit
NumberOfSharesIssuedPerUnit
1
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 blacu Common Stock Shares Excluded From Calculation Of Net Income Loss Per Share
CommonStockSharesExcludedFromCalculationOfNetIncomeLossPerShare
7330000
CY2023 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
540811
CY2023 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
0
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
540811
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0
CY2023 blacu Effective Income Tax Rate Reconciliation Permanent Differences Change In Fv Of Warrant Liability
EffectiveIncomeTaxRateReconciliationPermanentDifferencesChangeInFvOfWarrantLiability
0
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0
CY2023 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
0
CY2023 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.21
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2023Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued
0
CY2023 us-gaap Shortterm Debt Average Outstanding Amount
ShorttermDebtAverageOutstandingAmount
0
CY2023Q4 blacu Maximum Number Of Demands For Registration Of Securities
MaximumNumberOfDemandsForRegistrationOfSecurities
2
CY2023 blacu Effective Excise Tax Rate
EffectiveExciseTaxRate
1
CY2023 blacu Effective Excise Tax Rate
EffectiveExciseTaxRate
1
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023 us-gaap Common Stock Voting Rights
CommonStockVotingRights
Common stockholders of record are entitled to one vote for each share held on all matters to be voted on by stockholders.
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
7330000
CY2023Q4 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
36605106

Files In Submission

Name View Source Status
0001193125-24-099137-index-headers.html Edgar Link pending
0001193125-24-099137-index.html Edgar Link pending
0001193125-24-099137.txt Edgar Link pending
0001193125-24-099137-xbrl.zip Edgar Link pending
blacu-20231231.xsd Edgar Link pending
d781246d10k.htm Edgar Link pending
d781246dex211.htm Edgar Link pending
d781246dex311.htm Edgar Link pending
d781246dex312.htm Edgar Link pending
d781246dex321.htm Edgar Link pending
d781246dex322.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
blacu-20231231_def.xml Edgar Link unprocessable
blacu-20231231_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
blacu-20231231_pre.xml Edgar Link unprocessable
d781246d10k_htm.xml Edgar Link completed
blacu-20231231_cal.xml Edgar Link unprocessable